Anti Inflammatory News and Research RSS Feed - Anti Inflammatory News and Research

New study shows cannabinoid cannabidiol can help heal bone fractures

New study shows cannabinoid cannabidiol can help heal bone fractures

Cannabis -- marijuana, hashish -- was used as a go-to medical remedy by societies around the world for centuries. But the therapeutic use of marijuana was banned in most countries in the 1930s and '40s due to a growing awareness of the dangers of addiction. The significant medical benefits of marijuana in alleviating symptoms of such diseases as Parkinson's, cancer, and multiple sclerosis have only recently been reinvestigated. [More]
Nitric oxide released through nanotechnology may be a new way to treat, prevent acne

Nitric oxide released through nanotechnology may be a new way to treat, prevent acne

GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology. [More]
Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients

Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients

End-stage renal disease (ERSD) is the last stage of chronic kidney disease where the kidneys function at under 10 to 15 percent of their normal capacity. At this stage, kidneys cannot effectively remove waste or excess fluid from the blood system, and dialysis or a kidney transplant is necessary to live. [More]
Aspirin may inhibit the growth of mesothelioma, shows study

Aspirin may inhibit the growth of mesothelioma, shows study

Aspirin may inhibit the growth of mesothelioma, an aggressive and deadly asbestos-related cancer, University of Hawai'i Cancer Center researchers have found. [More]
Abide Therapeutics begins Phase 1a study of ABX-1431 investigational endocannabinoid system modulator

Abide Therapeutics begins Phase 1a study of ABX-1431 investigational endocannabinoid system modulator

Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of enrollment and dosing of the first subject in a Phase 1a clinical study of ABX-1431, a first-in-class, investigational endocannabinoid system modulator. [More]
Common arthritis drug could help to treat patients with blood cancers

Common arthritis drug could help to treat patients with blood cancers

Scientists at the University of Sheffield have discovered that a common drug given to arthritis sufferers could also help to treat patients with blood cancers. [More]
Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US. [More]
New NEI study shows that microglia can accelerate damage wrought by blinding eye disorders

New NEI study shows that microglia can accelerate damage wrought by blinding eye disorders

Spider-like cells inside the brain, spinal cord and eye hunt for invaders, capturing and then devouring them. These cells, called microglia, often play a beneficial role by helping to clear trash and protect the central nervous system against infection. But a new study by researchers at the National Eye Institute (NEI) shows that they also accelerate damage wrought by blinding eye disorders, such as retinitis pigmentosa. [More]
Dr. Jian-Dong Li receives $1.6 million to develop novel therapeutic targets to treat middle-ear infections

Dr. Jian-Dong Li receives $1.6 million to develop novel therapeutic targets to treat middle-ear infections

Dr. Jian-Dong Li, a professor and director of the Institute for Biomedical Sciences at Georgia State University and a Georgia Research Alliance Eminent Scholar in Inflammation and Immunity, has received a five-year, $1.6 million federal grant to develop novel anti-inflammatory therapeutics against middle-ear infections. [More]
Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Egalet Corporation today announced positive results from a Category 3 intranasal human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. [More]
New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions. [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

Cell transplantation researchers have successfully used bone marrow-derived mesenchymal stromal cells (MSCs) to treat a variety of diseases and conditions. Now, using injections of MSCs, a research team in Brazil has successfully treated laboratory rats modeled with severe burns. [More]
Pioglitazone drug significantly decreases risk of dementia

Pioglitazone drug significantly decreases risk of dementia

Patients with type 2 diabetes have a dysfunctional sugar metabolism because the essential hormone insulin does not work effectively. Once the disease reaches an advanced stage, the body stops producing insulin altogether, which means that it has to be administered externally. [More]
Statins benefit patients undergoing major lung resection, lower major complications

Statins benefit patients undergoing major lung resection, lower major complications

Statins have been shown to reduce complications from cardiovascular surgery. To determine whether statins might also help those undergoing major lung surgeries, a team at Memorial Sloan Kettering Cancer Center conducted a well-designed study that randomized patients to receive either a statin or placebo before and after surgery. [More]
ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

ScinoPharm Taiwan, Ltd. and Raffles PharmaTech announced today the collaboration to manufacture "Celecoxib," a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient (API). [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
OphthaliX enters into definitive agreement to purchase Improved Vision Systems

OphthaliX enters into definitive agreement to purchase Improved Vision Systems

OphthaliX Inc., a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd., announced today it has signed a definitive agreement to acquire Israel-based Improved Vision Systems Ltd. in a stock-for-stock transaction. [More]
Researchers discover that extreme exercise can lead to blood poisoning

Researchers discover that extreme exercise can lead to blood poisoning

Researchers have discovered that extreme exercise can cause intestinal bacteria to leak into the bloodstream, leading to blood poisoning. [More]
Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV for the commercialization of OMS103, Omeros' product for arthroscopic surgery. [More]
Advertisement
Advertisement